Filing Details

Accession Number:
0000950170-24-025083
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-04 18:12:04
Reporting Period:
2024-03-01
Accepted Time:
2024-03-04 18:12:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR Biological Products, (No Disgnostic Substances) (2836) 812992166
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821074 N. Bruce Jacobs C/O Kymera Therapeutics, Inc.
200 Arsenal Yards Blvd., Suite 230
Watertown MA 02472
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-01 31,250 $0.00 146,285 No 4 A Direct
Common Stock Disposition 2024-03-04 2,378 $41.41 143,907 No 4 S Direct
Common Stock Disposition 2024-03-04 1,301 $42.39 142,606 No 4 S Direct
Common Stock Disposition 2024-03-04 255 $43.26 142,351 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-03-01 187,500 $0.00 187,500 $43.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
187,500 2034-02-28 No 4 A Direct
Footnotes
  1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.
  2. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.